BIONIK Laboratories to Attend the 2022 American Occupational Therapy Association (AOTA) Conference & Expo
Company to Showcase its InMotion® ARM and ARM/HAND Rehabilitation & Mobility Solutions in San Antonio, Texas from March 31 - April 3, 2022
BOSTON--(BUSINESS WIRE)-- BIONIK Laboratories Corp. (OTCQB: BNKL) ("BIONIK" or the "Company"), a robotics company focused on providing rehabilitation and assistive technology solutions to stroke survivors and others with neurological and mobility challenges from hospital to home, today announced its participation in the American Occupational Therapy Association (AOTA) Conference in San Antonio, Texas from March 31 –April 3, 2022. The company will showcase its InMotion® technology at booth 801.
The AOTA Conference & Expo brings industry workers and professionals together to explore the latest updates on practice, professional issues, and trends. At this conference, BIONIK will highlight its InMotion® robotics ability to deliver intensive therapy to help patients regain motor function following a stroke and other neurological conditions or injuries. BIONIK’s new generation InMotion® ARM is an evidence-based neurorehabilitation technology that provides patients with real-time Assistance-as-Needed™. The InMotion® ARM quietly monitors the patient’s movements during therapy while it gently assists to help complete various motor therapy activities. While conventional therapy will allow physical therapists to complete 30-60 movements per session, BIONIK’s InMotion® ARM/HAND device allows clinicians to track up to 1,000 movements per session. InMotion® therapy guides the patient through specific tasks, aiming to improve motor control of the arm and hand by increasing strength, range of motion and coordination, and assisting with the provision of efficient, effective, and intensive sensorimotor therapy.
“We look forward to attending AOTA as their mission to advance occupational therapy practices, education and research aligns with BIONIK’s values. Our presence at AOTA gives us the opportunity to connect with our core audience, Occupational Therapists, and showcase how our devices, like the InMotion® ARM and ARM/HAND can help achieve the overall goal of improving a patient’s quality of life,” said Richard Russo, Jr., Chief Financial Officer and Interim Chief Executive Office of BIONIK. “Our attendance at this event allows us to share the benefits of our InMotion® devices as well as the ongoing training, education and support that we provide for patient results.”
InMotion® robots were developed according to the principles of motor learning and neuro-plasticity, using AI and measuring the position, the speed and the acceleration of the upper limb 200 times a second. The results center around the Company’s emphasis on technology adoption with its partner facilities to ensure successful utilization and patient results. The InMotion® robotic therapy systems are used regularly in more than 15 countries to help stroke survivors and those with other neurological conditions regain movement by training shoulder protraction/retraction, flexion/extension, abduction/adduction, internal/external rotation, and elbow flexion/extension. To learn more, please visit www.bioniklabs.com.
AOTA serves as a guiding light for the occupational therapy profession. Their mission statement guides to advance the work of occupational therapy practitioners, and their vision to lead the profession into the future. The association looks to advance occupational therapy practice, education, and research through standard setting and advocacy on behalf of its members, the profession, and the public.
About BIONIK Laboratories Corp.
BIONIK Laboratories is a robotics company focused on providing rehabilitation and mobility solutions to individuals with neurological and mobility challenges from hospital to home. The Company has a portfolio of products focused on upper and lower extremity rehabilitation for stroke and other mobility-impaired patients, including three products on the market and three products in varying stages of development.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons and other robotic rehabilitation products, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, pipeline of potential sales, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the market and projected market for our existing and planned products and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances, and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions, and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the inability to meet listing standards to uplist to a national stock exchange, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the impact on the Company’s business as a result of the Covid-19 pandemic, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company does not undertake to update these forward-looking statements.
Source: BIONIK Laboratories Corp.
Released March 30, 2022